Integrated clinical and genetic prognostic models with or without cytogenetic information provide an additional way to stratify risk for transplantation-age patients with primary myelofibrosis (PMF) and assimilate prognostically relevant clinical, cytogenetic, and mutation data, researchers concluded after conducting a study involving >800 individuals. Participants were ≤70 years of age and had PMF. Investigators looked at variables that predicted overall survival, and developed prognostic models both with and without cytogenic information. Among the results:

• Hemoglobin <100 g/L, leukocytes >25 × 109/L, platelets <100 × 109/L, circulating blasts ≥2%, bone marrow fibrosis grade ≥2, constitutional symptoms, absence of CALR type-1 mutation, presence of high-molecular risk mutation, and presence of ≥2 or more high-molecular risk mutations negatively impacted overall survival.
• The model without cytogenic information revealed low-, intermediate-, and high-risk categories; overall survival rates were 95%, 70%, and 29%, respectively.
• The model with cytogenic information revealed low-, intermediate-, high, and very-high risk categories; overall survival rates were 91%, 66%, 42%, and 7%, respectively.
• Both models remained effective after including older patients.